NCT04842877进行中（未招募）2 期
A Phase II Open-label Study Evaluating Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
The Lymphoma Academic Research Organisation22 个研究点 分布在 2 个国家目标入组 141 人开始时间: 2021年6月11日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 141
- 试验地点
- 22
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
This is a multicenter, prospective, single arm, non-randomized, open-label, phase 2 clinical study to evaluate safety and efficacy of valemetostat tosylate (DS-3201b) in patients with relapsed or refractory B cell lymphoma with 6 cohorts of patients including 2 biology-driven cohorts. Up to 141 patients will be enrolled in 6 different cohorts (40 patients with aggressive B-cell lymphoma, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL patients with EZH2 mutant (gain of function mutations) will be enrolled in the cohort 2bis. At least 8 aggressive B-cell lymphoma patients with EZH2 mutant will be enrolled in the cohort 1. The primary endpoint is the overall response rate (ORR) determined by investigator assessment.
详细描述
Each cycle consists of 28 days. Valemetostat tosylate (DS-3201b) is given continuously at 200 mg once daily (QD). The total duration is expected to be approximately 3 years, assuming an expected enrollment duration of 2 years and a minimum duration of valemetostat tosylate (DS- 3201b) administration of 12 cycles of 28 days for the last enrolled patient.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 - Participants with confirmed histological diagnosis of B-cell non-Hodgkin's lymphoma of aggressive B-cell lymphoma (diffuse large B-cell lymphoma-not otherwise specified, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma-not otherwise specified and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement, transformed indolent lymphoma and grade 3b follicular lymphoma), FL (grade 1, 2, 3a), MCL, MZL or other indolent lymphoma (Waldenström macroglobulinemia), or HL according to the World Health Organization (WHO) 2016 classification of hematopoietic and lymphoid tissue.
- •2. Participant who had progressive disease (PD) or did not have a response (CR or PR) in previous systemic therapy, or relapsed or progressed after previous systemic therapy
- •Participant who has measurable disease by the Lugano criteria (ie longest diameter of a nodal site > 1.5cm and/or longest diameter of an extranodal site > 1.0 cm)
- •Participant who had previous standard therapy with at least: (note: patients having received prior CAR-T therapy can be enrolled):
- •For aggressive B-cell lymphoma : 1 prior line of therapy (in transformed indolent lymphoma patient must have received at least one line of treatment containing an anthracycline-based regimen before of after transformation) containing an anti-CD20 antibody and an anthracycline (unless anthracycline-based therapy is contraindicated) and if patient is considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following criteria:
- •Relapsed following, or refractory to, previous ASCT
- •Ineligible for intensification treatment due to age or significant comorbidity
- •Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
- •Refused intensification treatment and/or ASCT
- •For FL, MZL and other indolent non-Hodgkin's lymphoma (NHL): 2 prior lines of systemic therapy with at least one anti-CD20 monoclonal antibody. Local involved field radiotherapy for limited stage disease is not considered as a previous line. Subjects with prior ASCT may be included. Note: for Splenic Marginal Zone Lymphoma (SMZL), splenectomy is considered as one line; for Extranodal Marginal Zone Lymphoma (ENMZL), Helicobacter pylori eradication is not considered as a previous line.
- •For MCL: 2 prior lines including at least one immunochemotherapy and one BTK inhibitor.
- •For HL: 3 prior lines including at least one line with anthracycline-based chemotherapy (unless anthracycline-based therapy is contraindicated), one line containing brentuximab-vedotin and one line containing an anti-PD1 or anti-PDL1 antibody and must be considered unable to benefit from intensification treatment with autologous stem cell transplant (ASCT) as defined by at least one of the following criteria:
- •Relapsed following, or refractory to, previous ASCT
- •Did not achieve at least a partial response to a standard salvage regimen
- •Ineligible for intensification treatment due to age or significant comorbidity
- •Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
- •Refused intensification treatment and/or ASCT
- •Participant with Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Adequate renal function defined as calculated creatinine clearance ≥ 40 mL/min per the Cockcroft and Gault formula
- •Adequate bone marrow function:
- •Absolute neutrophil count (ANC) > 1000/mm3 (≥ 1 × 109/L) without growth factor support (G-CSF) for at least 7 days
- •Platelets ≥ 75,000/mm3 (≥ 75 × 109/L) evaluated after at least 7 days since last platelet transfusion
- •Hemoglobin > 8.0 g/dL evaluated after at least 7 days since last transfusion
- •Adequate liver function:
- •Total bilirubin < 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia due to Gilbert's syndrome
- •Alkaline phosphatase (ALP) (in the absence of bone disease), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) < 3 × ULN (< 5 × ULN if subject has liver involvement due to lymphoma)
- •Adequate tissue (surgical excision is recommended) for central pathology review and biological characterisation
- •Patient being successfully tested for EZH2 mutation status at study specific laboratories (for cohort 1, 2 and 2bis)
- •Subjects with a history of hepatitis B or C are eligible on the condition that subjects have adequate liver function and are hepatitis B surface antigen negative and have undetectable serum hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA, respectively.
- •12. Females of childbearing potential must agree to use an highly effective birth control methods (defined in §13.6.1) during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 3 months after discontinuation of study treatment
- •Males with partners of childbearing potential must agree to use highly effective birth control methods during the study and 3 months after last treatment administration
- •Male and female participant ≥18 years of age at the time of informed consent
- •Patient covered by any social security system (France)
- •Patient who understands and speaks one of the country official language
- •Participant who has provided written consent to participate in the study
排除标准
- •Participant with prior exposure to EZH2 inhibitor
- •Participant with active lymphomatous involvement of the central nervous system (CNS) at screening
- •Any prior treatment-related (ie, chemotherapy, immunotherapy, radiotherapy), clinically significant toxicities have not resolved to ≤ Grade 1 per CTCAE version 5.0, or prior treatment-related toxicities are clinically unstable and clinically significant at time of enrollment.
- •Major surgery within 4 weeks before the first dose of study drug.
- •Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, or vomiting) that might impair the bioavailability of the drug
- •Subjects currently taking medications that are known moderate or strong CYP3A inducers
- •If currently used, these medications need to be discontinued at least 14 days prior to study drug administration; replacement by alternative medications that are not moderate or strong CYP3A inducers can be considered according to medical need
- •Vaccinated with live, attenuated vaccines within 6 months of enrollment (except COVID vaccine)
- •Use of any standard or experimental anti-cancer drug therapy within 4 weeks or a minimum of 3 half lives of the drug, whatever the shortest prior to first administration of study drug,
- •History of CAR T-cells therapy within 30 days prior to the first dose of study drug
- •History of autologous or allogeneic hematopoietic cell transplantation (HCT) within 90 days prior to the first dose of study drug
- •Patients taking corticosteroids within 2 weeks prior to first administration of study drug, unless administered at a cumulated dose equivalent of prednisone to ≤ 10mg /day (within these 2 weeks).
- •Participant with significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug; or cardiac ventricular arrhythmia
- •Subjects with malignancies other than B cell lymphomas except subjects who have been disease-free for 2 years (subjects with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible).
- •Positive serology of human immunodeficiency virus (HIV)
- •Participant with prolongation of corrected QT interval using Fridericia's formula (QTcF) to > 470 milliseconds (msec) (obtained on average of 3 ECGs)
- •Participant with venous thrombosis or pulmonary embolism not treated
- •Participant with complications of hepatic cirrhosis, interstitial pneumonia, or pulmonary fibrosis
- •Participant with active infection requiring systemic therapy
- •Woman who are pregnant (positive serum pregnancy test at screening) or breastfeeding
- •Participant who were deemed as inappropriate to participate in the study by the investigator or coinvestigator
研究组 & 干预措施
Experimental arm
Experimental
Experimental arm: Valemetostat tosylate (DS-3201b) is given continuously at 200 mg QD.
干预措施: Valemetostat tosylate (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: when mature response rate data have been observed, estimated as no later than 12 months after the last patient in each cohort has received the first dose of study drug
ORR according to Lugano Response Criteria (2014)
次要结局
- Complete Response (CR) Rate(After 12 cycles of treatment (each cycle of 28 days, id est (ie) 12 months))
- Complete Response Rate (CRR)(After 3 cycles of treatment (each cycle of 28 days, id est (ie) 3 months))
- Progression-Free Survival (PFS)(After 12 cycles(each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study))
- Duration of response (DoR)(After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study))
- Time to Response (TTR)(After 12 cycles (each cycle is 28 days) of study treatment for the last patient included (estimated 3 years of study))
- Number of Serious Adverse Events (SAE)(After 12 cycles of study treatment (each cycle is 28 days) for the last patient included (estimated 3 years of study))
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(predose at Cycle1 Day 22)
- Complete Response (CR) Rate(After 6 cycles of treatment (each cycle of 28 days, id est (ie) 6 months))
- Complete Response (CR) Rate(After 9 cycles of treatment (each cycle of 28 days, id est (ie) 9 months))
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(predose)
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(1 hour post-dose at Cycle1 Day 1)
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(2 hours post-dose at Cycle1 Day 1)
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(4 hours post-dose at Cycle1 Day 1)
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(5 hours post-dose at Cycle1 Day 1)
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(predose at Cycle1 Day 8)
- Pharmacokinetics: quantity of valemetostat tosylate (DS-3201b) and major metabolite (CALZ-1809a)(predose at Cycle1 Day 15)
研究者
研究点 (22)
Loading locations...
相似试验
进行中（未招募）
1 期
To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocytic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases.newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)MedDRA version: 17.1 Level: LLT Classification code 10054439 Term: Juvenile chronic myelomonocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851MedDRA version: 17.1 Level: PT Classification code 10023249 Term: Juvenile chronic myelomonocytic leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002388-13-ESCelgene Corporation55
进行中（未招募）
1 期
To determine the safety, clinical efficacy, and effect of azacitidine on the body and the DNA structure in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases.newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)MedDRA version: 17.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 17.1Level: PTClassification code 10023249Term: Juvenile chronic myelomonocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002388-13-NLCelgene Corporation28
进行中（未招募）
1 期
To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases.newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)MedDRA version: 20.0 Level: LLT Classification code 10054439 Term: Juvenile chronic myelomonocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851MedDRA version: 20.1 Level: PT Classification code 10023249 Term: Juvenile chronic myelomonocytic leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002388-13-CZCelgene Corporation28
进行中（未招募）
1 期
To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases.newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)MedDRA version: 20.0 Level: LLT Classification code 10054439 Term: Juvenile chronic myelomonocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851MedDRA version: 20.1 Level: PT Classification code 10023249 Term: Juvenile chronic myelomonocytic leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002388-13-IECelgene Corporation55
进行中（未招募）
不适用
To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases.newly diagnosed advanced myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) prior to hematopoietic stem cell transplantation (HSCT)MedDRA version: 17.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: HLTClassification code 10028536Term: Myelodysplastic syndromesSystem Organ Class: 100000004851MedDRA version: 17.1Level: PTClassification code 10023249Term: Juvenile chronic myelomonocytic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002388-13-ITCelgene Corporation55